624 related articles for article (PubMed ID: 30721294)
1. Effect of Magnetic Resonance Imaging vs Conventional Treat-to-Target Strategies on Disease Activity Remission and Radiographic Progression in Rheumatoid Arthritis: The IMAGINE-RA Randomized Clinical Trial.
Møller-Bisgaard S; Hørslev-Petersen K; Ejbjerg B; Hetland ML; Ørnbjerg LM; Glinatsi D; Møller J; Boesen M; Christensen R; Stengaard-Pedersen K; Madsen OR; Jensen B; Villadsen JA; Hauge EM; Bennett P; Hendricks O; Asmussen K; Kowalski M; Lindegaard H; Nielsen SM; Bliddal H; Krogh NS; Ellingsen T; Nielsen AH; Balding L; Jurik AG; Thomsen HS; Østergaard M
JAMA; 2019 Feb; 321(5):461-472. PubMed ID: 30721294
[TBL] [Abstract][Full Text] [Related]
2. Impact of a magnetic resonance imaging-guided treat-to-target strategy on disease activity and progression in patients with rheumatoid arthritis (the IMAGINE-RA trial): study protocol for a randomized controlled trial.
Møller-Bisgaard S; Hørslev-Petersen K; Ejbjerg BJ; Boesen M; Hetland ML; Christensen R; Møller J; Krogh NS; Stengaard-Pedersen K; Østergaard M
Trials; 2015 Apr; 16():178. PubMed ID: 25896862
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy of a 2-year MRI treat-to-target strategy on disease activity and radiographic progression in patients with rheumatoid arthritis in clinical remission: 5-year follow-up of the IMAGINE-RA randomised trial.
Møller-Bisgaard S; Hørslev-Petersen K; Ørnbjerg LM; Ejbjerg B; Hetland ML; Møller JM; Nielsen SM; Glinatsi D; Boesen M; Stengaard-Pedersen K; Madsen OR; Jensen B; Villadsen JA; Hauge EM; Hendricks O; Lindegaard H; Krogh NS; Jurik AG; Thomsen H; Christensen R; Østergaard M
RMD Open; 2024 Mar; 10(1):. PubMed ID: 38490697
[TBL] [Abstract][Full Text] [Related]
4. Effect of initiating biologics compared to intensifying conventional DMARDs on clinical and MRI outcomes in established rheumatoid arthritis patients in clinical remission: Secondary analyses of the IMAGINE-RA trial.
Møller-Bisgaard S; Hørslev-Petersen K; Ejbjerg B; Hetland ML; Christensen R; Ørnbjerg LM; Glinatsi D; Møller JM; Boesen M; Stengaard-Pedersen K; Madsen OR; Jensen B; Villadsen JA; Hauge EM; Bennett P; Hendricks O; Asmussen K; Kowalski M; Lindegaard H; Bliddal H; Krogh NS; Ellingsen T; Nielsen AH; Larsen L; Jurik AG; Thomsen HS; Østergaard M
Scand J Rheumatol; 2022 Jul; 51(4):268-278. PubMed ID: 34474649
[TBL] [Abstract][Full Text] [Related]
5. Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission.
Møller-Bisgaard S; Georgiadis S; Hørslev-Petersen K; Ejbjerg B; Hetland ML; Ørnbjerg LM; Glinatsi D; Møller J; Boesen M; Stengaard-Pedersen K; Madsen OR; Jensen B; Villadsen JA; Hauge EM; Bennett P; Hendricks O; Asmussen K; Kowalski M; Lindegaard H; Bliddal H; Krogh NS; Ellingsen T; Nielsen AH; Balding L; Jurik AG; Thomsen HS; Østergaard M
Rheumatology (Oxford); 2021 Jan; 60(1):380-391. PubMed ID: 32929463
[TBL] [Abstract][Full Text] [Related]
6. Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial.
Dale J; Stirling A; Zhang R; Purves D; Foley J; Sambrook M; Conaghan PG; van der Heijde D; McConnachie A; McInnes IB; Porter D
Ann Rheum Dis; 2016 Jun; 75(6):1043-50. PubMed ID: 27026689
[TBL] [Abstract][Full Text] [Related]
7. Conventional versus ultrasound treat to target: no difference in magnetic resonance imaging inflammation or joint damage over 2 years in early rheumatoid arthritis.
Sundin U; Aga AB; Skare Ø; Nordberg LB; Uhlig T; Hammer HB; van der Heijde D; Kvien TK; Lillegraven S; Haavardsholm EA;
Rheumatology (Oxford); 2020 Sep; 59(9):2550-2555. PubMed ID: 31999341
[TBL] [Abstract][Full Text] [Related]
8. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA).
Hetland ML; Ejbjerg B; Hørslev-Petersen K; Jacobsen S; Vestergaard A; Jurik AG; Stengaard-Pedersen K; Junker P; Lottenburger T; Hansen I; Andersen LS; Tarp U; Skjødt H; Pedersen JK; Majgaard O; Svendsen AJ; Ellingsen T; Lindegaard H; Christensen AF; Vallø J; Torfing T; Narvestad E; Thomsen HS; Ostergaard M;
Ann Rheum Dis; 2009 Mar; 68(3):384-90. PubMed ID: 18388160
[TBL] [Abstract][Full Text] [Related]
9. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints.
Aletaha D; Smolen JS
Arthritis Rheum; 2011 Dec; 63(12):3702-11. PubMed ID: 21953215
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial.
Brahe CH; Østergaard M; Johansen JS; Defranoux N; Wang X; Bolce R; Sasso EH; Ørnbjerg LM; Hørslev-Petersen K; Stengaard-Pedersen K; Junker P; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll C; Jørgensen A; Krintel SB; Raun J; Hetland ML
Scand J Rheumatol; 2019 Jan; 48(1):9-16. PubMed ID: 29985080
[TBL] [Abstract][Full Text] [Related]
11. Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: associations to future good radiographic and physical outcomes.
Paulshus Sundlisæter N; Aga AB; Olsen IC; Hammer HB; Uhlig T; van der Heijde D; Kvien TK; Lillegraven S; Haavardsholm EA;
Ann Rheum Dis; 2018 Oct; 77(10):1421-1425. PubMed ID: 29934373
[TBL] [Abstract][Full Text] [Related]
12. Silent progression in patients with rheumatoid arthritis: is DAS28 remission an insufficient goal in RA? Results from the German Remission-plus cohort.
Sewerin P; Vordenbaeumen S; Hoyer A; Brinks R; Buchbender C; Miese F; Schleich C; Klein S; Schneider M; Ostendorf B
BMC Musculoskelet Disord; 2017 Apr; 18(1):163. PubMed ID: 28420375
[TBL] [Abstract][Full Text] [Related]
13. Anti-cyclic citrullinated peptide antibodies, 28-joint Disease Activity Score, and magnetic resonance imaging bone oedema at baseline predict 11 years' functional and radiographic outcome in early rheumatoid arthritis.
Hetland ML; Østergaard M; Stengaard-Pedersen K; Junker P; Ejbjerg B; Jacobsen S; Ellingsen T; Lindegaard H; Pødenphant J; Vestergaard A; Jurik AG; Krogh NS; Hørslev-Petersen K;
Scand J Rheumatol; 2019 Jan; 48(1):1-8. PubMed ID: 30101636
[TBL] [Abstract][Full Text] [Related]
14. Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort.
Lillegraven S; Prince FH; Shadick NA; Bykerk VP; Lu B; Frits ML; Iannaccone CK; Kvien TK; Haavardsholm EA; Weinblatt ME; Solomon DH
Ann Rheum Dis; 2012 May; 71(5):681-6. PubMed ID: 21994234
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, randomized controlled trial to compare the effect of biannual peripheral magnetic resonance imaging, radiography and standard of care disease progression monitoring on pharmacotherapeutic escalation in rheumatoid and undifferentiated inflammatory arthritis: study protocol for a randomized controlled trial.
Tavares R; Beattie KA; Bensen WG; Bobba RS; Cividino AA; Finlay K; Goeree R; Hart LE; Jurriaans E; Larche MJ; Parasu N; Tarride JE; Webber CE; Adachi JD
Trials; 2014 Jul; 15():268. PubMed ID: 24997587
[TBL] [Abstract][Full Text] [Related]
16. Sustained beneficial effects of a protocolized treat-to-target strategy in very early rheumatoid arthritis: three-year results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort.
Vermeer M; Kuper HH; Moens HJ; Drossaers-Bakker KW; van der Bijl AE; van Riel PL; van de Laar MA
Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1219-26. PubMed ID: 23436821
[TBL] [Abstract][Full Text] [Related]
17. Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial.
Lillegraven S; Paulshus Sundlisæter N; Aga AB; Sexton J; Olsen IC; Fremstad H; Spada C; Madland TM; Høili CA; Bakland G; Lexberg Å; Hansen IJW; Hansen IM; Haukeland H; Ljoså MA; Moholt E; Uhlig T; Solomon DH; van der Heijde D; Kvien TK; Haavardsholm EA
JAMA; 2021 May; 325(17):1755-1764. PubMed ID: 33944875
[TBL] [Abstract][Full Text] [Related]
18. Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials.
Brahe CH; Dehlendorff C; Østergaard M; Johansen JS; Ørnbjerg LM; Hørslev-Petersen K; Stengaard-Pedersen K; Junker P; Ellingsen T; Lindegaard H; Hansen I; Lottenburger T; Jacobsen S; Jurik AG; Hetland ML
Scand J Rheumatol; 2018 Jul; 47(4):259-269. PubMed ID: 29336711
[TBL] [Abstract][Full Text] [Related]
19. Early clinical response and long-term radiographic progression in recent-onset rheumatoid arthritis: Clinical remission within six months remains the treatment target.
Legrand J; Kirchgesner T; Sokolova T; Vande Berg B; Durez P
Joint Bone Spine; 2019 Oct; 86(5):594-599. PubMed ID: 30928534
[TBL] [Abstract][Full Text] [Related]
20. Synovitis and osteitis are very frequent in rheumatoid arthritis clinical remission: results from an MRI study of 294 patients in clinical remission or low disease activity state.
Gandjbakhch F; Conaghan PG; Ejbjerg B; Haavardsholm EA; Foltz V; Brown AK; Møller Døhn U; Lassere M; Freeston J; Bøyesen P; Bird P; Fautrel B; Hetland ML; Emery P; Bourgeois P; Hørslev-Petersen K; Kvien TK; McQueen F; Ostergaard M
J Rheumatol; 2011 Sep; 38(9):2039-44. PubMed ID: 21885514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
